Discovery Life Sciences Acquires AllCells
July 12, 2022
Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.
- Buyers
- Discovery Life Sciences
- Targets
- AllCells
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Discovery Life Sciences Acquires ReachBio Research Labs
April 11, 2023
Biotechnology
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
Eurofins Discovery Acquires DiscoveryBioMed
July 5, 2022
Biotechnology
Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.
-
Beam Global Acquires AllCell Technologies
February 23, 2022
Energy
Beam Global (Nasdaq: BEEM) entered into a definitive asset purchase agreement to acquire AllCell Technologies in an all-stock transaction, combining Beam’s EV charging and clean-energy products with AllCell’s battery engineering and manufacturing. The deal is intended to secure Beam’s battery supply chain, expand manufacturing and IP capabilities, reduce COGS, and accelerate product development across EV, micro-mobility, aviation and stationary energy markets.
-
CellCarta Acquires Biogazelle
December 14, 2021
Biotechnology
CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.
-
Integra LifeSciences Acquires ACell, Inc.
December 16, 2020
Medical Devices
Integra LifeSciences agreed to acquire regenerative-medicine company ACell, Inc. for $300 million upfront in cash plus up to $100 million in revenue-based milestones. The acquisition adds ACell's MatriStem porcine urinary bladder matrix platform to Integra's tissue technologies portfolio and is expected to close in Q1 2021, subject to customary conditions.
-
Lonza AG Acquires PharmaCell BV
June 1, 2017
Biotechnology
Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.